Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Rises By 91.3%

TScan Therapeutics, Inc. (NASDAQ:TCRX) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 419,700 shares, an increase of 91.3% from the March 31st total of 219,400 shares. Based on an average daily trading volume, of 193,600 shares, the days-to-cover ratio is currently 2.2 days. Approximately 1.1% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

TCRX has been the topic of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and set a $10.00 price objective on shares of TScan Therapeutics in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Thursday, March 7th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pale Fire Capital SE purchased a new position in shares of TScan Therapeutics during the 3rd quarter valued at approximately $42,000. Letko Brosseau & Associates Inc. purchased a new position in shares of TScan Therapeutics during the 3rd quarter valued at approximately $83,000. Cannon Global Investment Management LLC purchased a new position in shares of TScan Therapeutics during the 1st quarter valued at approximately $139,000. Finally, abrdn plc purchased a new position in shares of TScan Therapeutics during the 4th quarter valued at approximately $1,166,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Stock Performance

Shares of NASDAQ TCRX traded up $0.03 during midday trading on Friday, reaching $7.32. 92,052 shares of the stock were exchanged, compared to its average volume of 210,320. The firm has a market cap of $350.50 million, a price-to-earnings ratio of -3.87 and a beta of 0.90. TScan Therapeutics has a twelve month low of $1.62 and a twelve month high of $9.00. The firm has a 50-day simple moving average of $7.19 and a two-hundred day simple moving average of $5.82. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.18.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The business had revenue of $7.21 million for the quarter, compared to analysts’ expectations of $2.94 million. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. As a group, analysts anticipate that TScan Therapeutics will post -1.03 EPS for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.